Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Emmy W Verschuren"'
Autor:
Mike Mason, Óscar Lapuente-Santana, Anni S. Halkola, Wenyu Wang, Raghvendra Mall, Xu Xiao, Jacob Kaufman, Jingxin Fu, Jacob Pfeil, Jineta Banerjee, Verena Chung, Han Chang, Scott D. Chasalow, Hung Ying Lin, Rongrong Chai, Thomas Yu, Francesca Finotello, Tuomas Mirtti, Mikko I. Mäyränpää, Jie Bao, Emmy W. Verschuren, Eiman I. Ahmed, Michele Ceccarelli, Lance D. Miller, Gianni Monaco, Wouter R. L. Hendrickx, Shimaa Sherif, Lin Yang, Ming Tang, Shengqing Stan Gu, Wubing Zhang, Yi Zhang, Zexian Zeng, Avinash Das Sahu, Yang Liu, Wenxian Yang, Davide Bedognetti, Jing Tang, Federica Eduati, Teemu D. Laajala, William J. Geese, Justin Guinney, Joseph D. Szustakowski, Benjamin G. Vincent, David P. Carbone
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Background Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from the Anti–PD-1 Response Prediction DREAM Challenge, a crowdsourc
Externí odkaz:
https://doaj.org/article/c3635bd5bd234a2da3cffc46f246670f
Autor:
Sarang S. Talwelkar, Mikko I. Mäyränpää, Julia Schüler, Nora Linnavirta, Annabrita Hemmes, Simone Adinolfi, Matti Kankainen, Wolfgang Sommergruber, Anna‐Liisa Levonen, Jari Räsänen, Aija Knuuttila, Emmy W. Verschuren, Krister Wennerberg
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 747-764 (2023)
Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome for non‐small‐cell lung cancer (NSCLC) patients with ALK‐rearranged tumors. However, clinical resistance typically develops over time and, in the majority
Externí odkaz:
https://doaj.org/article/1563d14766b740a0a1ffecc8176e6bc3
Autor:
Tatiana V. Kudling, James H.A. Clubb, Santeri Pakola, Dafne C.A. Quixabeira, Iris A.K. Lähdeniemi, Camilla Heiniö, Victor Arias, Riikka Havunen, Victor Cervera-Carrascon, Joao M. Santos, Eva Sutinen, Jari Räsänen, Kristian Borenius, Mikko I. Mäyränpää, Eero Aaltonen, Suvi Sorsa, Otto Hemminki, Anna Kanerva, Emmy W. Verschuren, Ilkka Ilonen, Akseli Hemminki
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTLung cancer remains among the most difficult-to-treat malignancies and is the leading cause of cancer-related deaths worldwide. The introduction of targeted therapies and checkpoint inhibitors has improved treatment outcomes; however, most pa
Externí odkaz:
https://doaj.org/article/0795eae91aef4daa81fbde09829253f2
Autor:
Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, Otto Hemminki, Anna Kanerva, João Manuel Santos, Camilla Heiniö, Jari Räsänen, Suvi Sorsa, Santeri A Pakola, James Clubb, Tatiana V Kudling, Susanna AM Grönberg-Vähä-Koskela, Victor Arias, Dafne Alves Quixabeira, Iris Lähdeniemi, Eva Sutinen, Kristian Borenius, Mikko Mäyränpää, Eero Altonen, Emmy W Verschuren, Ilkka Ilonen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b558acb986684d68b325206f8f881136
Autor:
Iris A. K. Lähdeniemi, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar, Jie Bao, Nora Linnavirta, Ceren Şeref Vujaklija, Elina A. Kiss, Annabrita Hemmes, Emmy W. Verschuren
Publikováno v:
Biology Open, Vol 11, Iss 12 (2022)
Externí odkaz:
https://doaj.org/article/c0f7ba253ae148818c5beb30806d7339
Autor:
Sarang S. Talwelkar, Iris A.K. Lähdeniemi, Mikko I. Mäyränpää, Annabrita Hemmes, Nora Linnavirta, Jari Räsänen, Aija Knuuttila, Krister Wennerberg, Emmy W. Verschuren
Publikováno v:
STAR Protocols, Vol 3, Iss 4, Pp 101720- (2022)
Summary: Drug sensitivity data acquired from solid tumor-derived cultures are often unsuitable for personalized treatment guidance due to the lengthy turnaround time. Here, we present a protocol for determining ex vivo drug sensitivities using fresh
Externí odkaz:
https://doaj.org/article/006c6459adf0456781a8ab0e155bc7a4
Autor:
Ashwini S. Nagaraj, Jenni Lahtela, Annabrita Hemmes, Teijo Pellinen, Sami Blom, Jennifer R. Devlin, Kaisa Salmenkivi, Olli Kallioniemi, Mikko I. Mäyränpää, Katja Närhi, Emmy W. Verschuren
Publikováno v:
Cell Reports, Vol 18, Iss 3, Pp 673-684 (2017)
Lung cancers exhibit pronounced functional heterogeneity, confounding precision medicine. We studied how the cell of origin contributes to phenotypic heterogeneity following conditional expression of KrasG12D and loss of Lkb1 (Kras;Lkb1). Using proge
Externí odkaz:
https://doaj.org/article/4865c03d589649f090200e998d1e2cd4
Autor:
Emmy W. Verschuren, Krister Wennerberg, Mikko I. Mäyränpää, Kaisa Salmenkivi, Pipsa Saharinen, Elina A. Kiss, Swapnil Potdar, Annabrita Hemmes, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar
Table_S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27859c01a5a1785161bc7a7bd455ec8a
https://doi.org/10.1158/1535-7163.22509207.v1
https://doi.org/10.1158/1535-7163.22509207.v1
Autor:
Emmy W. Verschuren, Krister Wennerberg, Mikko I. Mäyränpää, Kaisa Salmenkivi, Pipsa Saharinen, Elina A. Kiss, Swapnil Potdar, Annabrita Hemmes, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar
Supplementary text and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25da8709577071f02aaeaf9cd8b88369
https://doi.org/10.1158/1535-7163.22509210.v1
https://doi.org/10.1158/1535-7163.22509210.v1
Autor:
Emmy W. Verschuren, Krister Wennerberg, Mikko I. Mäyränpää, Kaisa Salmenkivi, Pipsa Saharinen, Elina A. Kiss, Swapnil Potdar, Annabrita Hemmes, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar
Most non–small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or STK11/LKB1 alterations. By coupling ex vivo drug sensitivity profiling with in vivo drug response studies, we aimed to identify drug vulnerabilities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d26d521c92c9d7c4073c63d907f5285
https://doi.org/10.1158/1535-7163.c.6539226.v1
https://doi.org/10.1158/1535-7163.c.6539226.v1